BioSpace News Archive

Skanska has signed a contract to renovate a healthcare facility in New York, New York, USA.

GT Biopharma, Inc. announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 6,500,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 6,500,000 shares of common stock at a combined purchase price of $1.00 per share of common stock and associated warrant in a registered direct offering.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination and influenza stand-alone vaccine candidates.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced it will effect a reverse stock split of all outstanding shares of the company’s common stock at a ratio of 25 to 1.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022.

OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease to address the significant unmet need in this multi-billion-dollar market, announces its interim results for the six months ended 30 September 2022.

Calliditas Therapeutics AB partner Everest Medicines announced that the Center for Drug Evaluation of the China National Medical Products Administration has recommended Priority Review for the New Drug Application of Nefecon for the treatment of primary immunoglobulin A nephropathy in adults at risk of rapid disease progression.

Mentice AB, Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000.

OncoC4, Inc. announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer .